17/10/2022 - Institutional news
It will analyse the role the circadian rhythm alteration of intestinal microbiota plays in the development of Alzheimer's disease. The project is one of the sixty selected in the ninth call for applications for these grants, which reward highly innovative projects in nine areas of scientific knowledge and culture. The project by IMIM-Hospital del Mar researcher Patrick-Simon Welz, 'Losing the rhythm: host-microbiota circadian communication in Alzheimer's disease', is one of the 60 projects selected in the ninth edition of the Leonardo grants, awarded by the BBVA Foundation. These grants support highly innovative proposals in various scientific and cultural fields. This year, 884 applications were submitted and evaluated by 85 independent experts divided into nine panels.
17/10/2022 - Institutional news
The Section Chief of the Gastrointestinal Surgery Department at Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute became a corresponding member of the RAMC, in a ceremony held on 4 October at the institution's headquarters. Dr. Manuel Pera has been a corresponding member of the Royal Academy of Medicine of Catalonia since 4 October. The appointment was made in a ceremony held at the institution's headquarters, in which the Section Chief of the Surgery Department at Hospital del Mar and coordinator of the Gastroesophageal Carcinogenesis research group at the Hospital del Mar Medical Research Institute (IMIM), gave the speech, 'Improving the quality of care in digestive cancer surgery: the experience of the Spanish EURECCA Oesophagogastric Cancer Registry'. The presentation of the new member was led by Dr. Lluís Grande i Posa, full member of the RAMC and Emeritus Chief of Surgery at Hospital del Mar.
30/09/2022 - Events
After two years of pandemic next October 8th from 10:00 to 14:30h comes a new edition of the OpenPRBB to see and hear the science first hand. The different research centers of the PRBB will offer a wide range of free activities for the whole family. On Saturday morning, children over 12 years old will be able to learn about science from its protagonists with guided tours. From 10:00 to 13:30h we have prepared several routes that will simultaneously tour the building and visit different laboratories. In the case of the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) you will be able to visit the Clinical Trials Unit, the molecular cancer therapy, stem cell and cancer, critical pathology laboratories, the Neurovascular research group and the Biobank where each of them will explain what their work consists of and the research they are currently carrying out.
Més informació "Open PRBB 2022: On October 8, we reopen the doors to the public"
05/10/2022 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumour's ability to generate resistance to the most common biological treatment for HER2. The paper, published in the journal Nature Communications, demonstrates the ability of a new therapy, currently undergoing clinical trials, to promote a potent immune response by binding to the fibroblasts, enabling it to overcome resistance to anti-HER2 therapy in tumours with this cancer cell protection mechanism. To demonstrate this, the researchers created a 3D tumour model in which they were able to check the relationships between all the factors involved.
12/09/2022 - Press release
Patients admitted due to SARS-CoV-2 infection with imbalanced levels of two immune system cells, CD4 and CD8 T lymphocytes, have a worse prognosis and a higher risk of death. Having more than twice the number of CD4 lymphocytes than CD8 lymphocytes increases the probability of dying from the infection by 4.6 times and the chances of experiencing respiratory distress by two times, according to a study by physicians and researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute, Universitat Pompeu Fabra, and CIBERINFEC, published in the journal Frontiers in Medicine. This finding leads the study's authors to recommend a more aggressive therapeutic approach for these patients from the moment of admission. Additionally, they believe that this situation may be repeated in other viral infections.
23/08/2022 - General information
A team from Hospital del Mar and the Hospital del Mar Medical Research Institute has validated the technique involving breast biopsy guided by contrast mammography to visualise suspicious lesions that cannot be observed via ultrasound or mammography. After analysing data from tests performed on 64 women, they have been able to verify that this technique offers the same or better results than the other diagnostic tool used in these cases, magnetic resonance imaging (MRI). The results have been published in the journal European Radiology. In the cases studied, contrast mammography-guided breast biopsy was successful in 95.4% of cases. In only three tests was the visibility of the findings not as expected. In comparison, MRI has a success rate of between 87% and 98%.
Més informació "Usefulness of breast biopsy guided by contrast-enhanced mammography is validated"
17/08/2022 - General information
A joint research project from the Hospital del Mar Medical Research Institute and the CNIC has been selected to receive a grant from the Carlos III Health Institute to analyse whether a greater presence of omega-3 in the blood is associated with a brain that is more resistant to this neurodegenerative disease. The research project led by Dr. Aleix Sala-Vila, from the Cardiovascular Risk and Nutrition Research Group at IMIM-Hospital del Mar has received one of the research, development and innovation project grants from the Carlos III Health Institute. The study will be carried out in conjunction with the National Centre for Cardiovascular Research Carlos III (CNIC) as part of the PESA study that this institute is developing with Banco Santander. The initiative will receive 114,000 euros in funding.
Més informació "Research into whether a diet rich in omega-3 helps prevent Alzheimer's disease"
11/08/2022 - Press release
The research, led by the Barcelonaβeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the University of Gothenburg, has been published in the prestigious journal Nature Medicine. The study, which used data from almost 400 participants of the ALFA+ Study, which has the impetus of the "la Caixa" Foundation, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms. The results of this research make p-tau231 a very promising blood biomarker to detect early those middle-aged people who show the first brain changes associated with Alzheimer's and to conduct clinical trials aimed at this early stage of Alzheimer's.
01/08/2022 - General information
During the months of April, May and June, the cycle "Our brain, that great unknown" organized by the IMIM and the network of libraries of Barcelona, has been carried out with great success of attendees. More than 400 people have been able to participate in this cycle that is part of the "Visions of Science" project that the Barcelona Libraries have been carrying out for years. The cycle has lasted 8 weeks, was free and open to everyone. It dealt with topics related to the brain and allowed attendees to learn about the latest data provided by new scientific advances in this field thanks to the participation as speakers of the best experts from the Hospital del Mar and IMIM.
Més informació "Successful cycle "Our brain, that great unknown" with more than 400 attendees"
28/07/2023 - Press release
A study by cardiologists at Hospital del Mar and researchers at the Hospital del Mar Medical Research Institute reveals that more than half of the people treated for the arrhythmia known as atrial flutter will suffer an episode of atrial fibrillation in less than a year. The risk of atrial fibrillation reaches 86% in those patients who score higher on a risk scale designed by the team, prompting the need for more accurate monitoring of these patients because of the likelihood that they could suffer other cardiovascular problems, such as a stroke. The study, published in the Journal of Cardiology, was funded by the 2014 La Marató de TV3, dedicated to heart disease.
Més informació "Patients with arrhythmia are at greater risk of suffering atrial fibrillation"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact